Authors: Lei Qin Xiang Li Amanda Stroiney Jinrong Qu Jeffrey Helgager David A Reardon Geoffrey S Young
Publish Date: 2017/01/09
Volume: 59, Issue: 2, Pages: 135-145
Abstract
A retrospective analysis was performed on longitudinal MRIs obtained on recurrent GBM patients enrolled on clinical trials Among 10 patients with analyzable data bidirectional diameters were measured on contrast enhanced T1 pGdT1WI and volumes of interest VOI representing measurable abnormality suggestive of tumor were selected on pGdT1WI pGdT1 VOI FLAIRT2WI FLAIR VOI and ADC maps Intermediate ADC IADC VOI represented voxels within the FLAIR VOI having ADC in the range of highly cellular tumor 07–11 × 10−3 mm2/s IADC VOI Therapeutic benefit was determined by tissue pathology and survival on trial IADC VOI pGdT1 VOI FLAIR VOI and RANO assessment results were correlated with patient benefitFive patients were deemed to have received therapeutic benefit and the other five patients did not The average time on trial for the benefit group was 194 days as compared to 81 days for the no benefit group IADC VOI correlated well with the presence or absence of clinical benefit in 10 patients Furthermore pGd VOI FLAIR VOI and RANO assessment correlated less well with responseMRI reveals an initial increase in volumes of abnormal tissue with contrast enhancement edema and intermediate ADC suggesting hypercellularity within the first 0–6 months of immunotherapy Subsequent stabilization and improvement in IADC VOI appear to better predict ultimate therapeutic benefit from these agents than conventional imagingDAR reports personal fees from AbbVie personal fees from Bristol Myers Squibb personal fees from Cavion grants and personal fees from Celldex personal fees from Genentech Roche grants and personal fees from Inovio personal fees from Juno Pharmaceuticals personal fees from Merck grants and personal fees from Midatech personal fees from Momenta Pharmaceuticals personal fees from Novartis personal fees from Novocure personal fees from Oxigene personal fees from Regeneron personal fees from Stemline Therapeutics and grants from Incyte outside the submitted work
Keywords: